---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-039981"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:50:32.862054+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oncocyte Q3 rev $0.4M, op loss $6.5M; VitaGraft Kidney gets CMS coverage

## Summary
- Revenue $0.4M; net operating loss $6.5M vs $1.7M in Q3 2022 (which included $6.1M fair value benefit).
- Cash burn reduced to $3.6M; cash, equivalents, and marketable securities $14.2M as of Sep 30, 2023.
- VitaGraft Kidney received positive CMS coverage decision; commercial revenue expected in 1H 2024.
- R&D expense $2.2M (+48% YoY) driven by assay development; SG&A $2.5M (-56% YoY) due to lower stock compensation.
- VitaGraft Liver under review for CMS coverage at MolDX.

## SEC filing metadata
- accession: 0001493152-23-039981
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315223039981/0001493152-23-039981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315223039981/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-039981
- JSON: https://secwatch.observer/filing/0001493152-23-039981.json
- Plain text: https://secwatch.observer/filing/0001493152-23-039981.txt

## Key facts
- Earnings Releases
  Insight Molecular Diagnostics Inc. reported third quarter ended September 30, 2023 results: revenue $0.4 million, net income $6.5 million net consolidated operating loss.
  - Period: third quarter ended September 30, 2023
  - Revenue: $0.4 million
  - Net income: $6.5 million net consolidated operating loss
  - Result: reported results
  source text: for growth in 2024 and the years beyond,” concluded Mr. Riggs. Third Quarter 2023 Financial Results Consolidated revenue for the third quarter of 2023 was approximately $0.4 million primarily due to increased revenue from Pharma Services. Cost of revenue was approximately $0.2 million. Net consolidated operating loss for the three months ended September 30,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315223039981/0001493152-23-039981-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.